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ARTICLE
PD-1 blockade potentiates HIV latency
reversal ex vivo in CD4+ T cells from
ART-suppressed individuals
Rémi Fromentin1, Sandrina DaFonseca2, Cecilia T. Costiniuk3, Mohamed El-Far1, Francesco Andrea Procopio4,
Frederick M. Hecht 5, Rebecca Hoh5, Steven G. Deeks 5, Daria J. Hazuda6, Sharon R. Lewin7,8,
Jean-Pierre Routy 3, Rafick-Pierre Sékaly9 & Nicolas Chomont 1,10
HIV persists in latently infected CD4+ T cells during antiretroviral therapy (ART). Immune
checkpoint molecules, including PD-1, are preferentially expressed at the surface of persis-
tently infected cells. However, whether PD-1 plays a functional role in HIV latency and
reservoir persistence remains unknown. Using CD4+ T cells from HIV-infected individuals,
we show that the engagement of PD-1 inhibits viral production at the transcriptional level and
abrogates T-cell receptor (TCR)-induced HIV reactivation in latently infected cells. Con-
versely, PD-1 blockade with the monoclonal antibody pembrolizumab enhances HIV pro-
duction in combination with the latency reversing agent bryostatin without increasing T cell
activation. Our results suggest that the administration of immune checkpoint blockers to
HIV-infected individuals on ART may facilitate latency disruption.
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Latently infected cells carrying integrated human immuno-deficiency virus (HIV) genomes persist during antiretroviraltherapy (ART) and represent the main barrier to a cure1–3.
The establishment of latency may result from direct infection of
resting CD4+ T cells4 or from infection of CD4+ T cells transi-
tioning from an activated to a resting state5. Latently infected
CD4+ T cells are rare both before and after ART initiation6,7,
suggesting that HIV latency is established only in a small fraction
of CD4+ T cells.
Programmed cell death-1 (PD-1) is an immune checkpoint
molecule expressed at high levels on the surface of exhausted
HIV-specific CD4+ and CD8+ T cells8–12. Its blockade enhances
CD4+ T cells and CD8+ T cells functions during Simian
immunodeficiency virus infection13,14.
In addition to its role in T-cell exhaustion, PD-1 and other
immune checkpoint molecules such as lymphocyte activation
gene-3 (LAG-3) and T-cell immunoreceptor with Ig and ITIM
domains (TIGIT) are preferentially expressed at surface of per-
sistently infected CD4+ T cells15–17. Of note, follicular helper T
(Tfh) cells, which express high levels of PD-1, are major produ-
cers of viral particles in untreated HIV infection18 and serve as a
preferential reservoir for HIV during ART19,20. In addition, PD-1
and LAG-3 measured prior to ART strongly predict time to
return of viraemia upon treatment interruption21. However,
whether these molecules play an active role in the establishment
and maintenance of HIV latency remains unclear.
In an in vitro latency model, PD-1 blockade reduces the fre-
quency of latently infected CD4+ T cells22. Because PD-1 induces
T-cell quiescence and inhibits T-cell activation23, we hypothe-
sized that the engagement of the PD-1 pathway may directly
contribute to the establishment of viral latency by inhibiting viral
transcription and production. We demonstrate that the engage-
ment of PD-1 abrogates T-cell receptor (TCR)-induced HIV
reactivation in latently infected cells isolated from HIV-infected
individuals. Conversely, PD-1 blockade with the monoclonal
antibody pembrolizumab enhances HIV production induced by
the latency reversing agent bryostatin without increasing T-cell
activation. These results suggest that the administration of
immune checkpoint blockers to HIV-infected individuals on ART
may facilitate latency reversal in vivo.
Results
PD-1 marks HIV-infected cells in viremic individuals. To
determine if PD-1 could play a role in the establishment of HIV
latency, we first assessed the distribution of HIV in memory CD4
+ T cells expressing high and low levels of PD-1 in HIV-infected
individuals not receiving ART. We found that memory CD4+
T cells expressing PD-1 were preferentially infected, as demon-
strated by the higher frequency of integrated HIV DNA in PD-1
expressing central (TCM), transitional (TTM), and effector mem-
ory (TEM) cells as compared to their PD-1 negative (PD-1−)
counterparts (median fold-change: 6.5, 2.3, and 2.2, respectively,
Supplementary Fig. 1a). Accordingly, flow cytometry sorted PD-1
positive (PD-1+) cells produced higher levels of viral particles,
indicating that PD-1+ cells are major targets for productive HIV
infection during untreated disease (Supplementary Fig. 1b).
PD-1 engagement inhibits viral production. To determine the
impact of PD-1 engagement on HIV production, we stimulated
productively infected CD4+ T cells isolated from untreated HIV-
infected individuals in the presence or absence of PD-L1, one of
the two ligands for PD-1. TCR stimulation led to a marked
increase in the amount of the viral protein p24 measured in the
culture supernatant and this induction was dramatically reduced
in the presence of PD-L1 (98% inhibition, p < 0.0001, Fig. 1a and
Supplementary Fig. 1c). Of note, this effect was maintained over
time, since the inhibition was still observed after 6 and 9 days of
culture (Fig. 1b, c and Supplementary Fig. 1d). Importantly, PD-
L1 acted directly on productively infected cells and not by
decreasing the permissiveness of bystander cells since the inhi-
bition of viral production was also observed in the presence of
antiretroviral drugs (ARVs) that block new infection events as
well as in short-term cultures (69–86% inhibition, Supplementary
Fig. 1e–g). To demonstrate the specificity of this mechanism, we
sorted PD-1+ and PD-1− memory CD4+ T cells and observed
that PD-L1− mediated inhibition was restricted to PD-1+ cells (p
= 0.01), since the ligand did not significantly affect viral pro-
duction in PD-1− cells (Fig. 1d).
To gain further insights into the mechanism by which PD-1
engagement inhibited HIV production, we transfected primary
CD4+ T cells with an LTR-luciferase reporter construct. The
engagement of PD-1 by PD-L1 resulted in a significant reduction
in the LTR activity, indicating that PD-1 exerted its inhibitory
effect on HIV production at the transcriptional level (p= 0.002,
Fig. 1e).
PD-1 inhibits viral reactivation in latently infected cells. Hav-
ing demonstrated that the engagement of PD-1 at the surface of
productively infected cells inhibited the viral production induced
by TCR stimulation, we next sought to determine if this phe-
nomenon could abrogate viral reactivation from latently infected
cells. Even after years of ART, PD-1 expression at the surface of
CD4+ T cells from virally suppressed individuals was not nor-
malized (Supplementary Fig. 2a), notably in the TTM and TEM
subsets (Supplementary Fig. 2b–e). Similarly, both PD-1 ligands
(PD-L1 and PD-L2) were expressed at higher levels at the surface
of CD4+ T cells and monocytes from fully suppressed individuals
when compared to uninfected controls (Supplementary Fig. 2f–i).
Of note, higher frequencies of CD4+ T cells expressing PD-1 were
detected in the rectum, colon, and terminal ileum of individuals
on ART when compared to matched blood and lymph nodes
(Supplementary Fig. 2j). These higher frequencies of CD4+
T cells expressing PD-1 was consistent with heightened fre-
quencies of differentiated memory CD4+ T cells (TTM and TEM)
in the gut compartment (Supplementary Fig. 2k). We further
confirmed our and others previous observations16,19,24 indicating
a strong positive correlation between the frequency of persistently
infected CD4+ T cells (as measured by integrated HIV DNA) and
PD-1 expression in CD4+ T cells during ART (r= 0.42,
p < 0.0001, Supplementary Fig. 3a) as well as the preferential
infection of PD-1+ TCM and TTM cells during ART by measuring
integrated HIV DNA (median fold-enrichment: 1.7, p= 0.01 and
1.6, p= 0.04, respectively, Supplementary Fig. 3b). In addition,
using the tat/rev induced limiting dilution assay (TILDA) and
quantitative viral outgrowth assay, we observed that inducible and
replication-competent proviruses were enriched in CD4+ T cells
expressing PD-1 in the majority of the samples tested (Supple-
mentary Fig. 3c, d).
To assess the effect of PD-1 engagement on viral reactivation
from latency, we stimulated CD4+ T cells from virally suppressed
individuals in the presence or absence of PD-L1. TCR stimulation
led to readily detectable levels of viral production that were
dramatically reduced in the presence of PD-L1 (89% inhibition, p
< 0.0001, Fig. 2a), demonstrating that PD-1 engagement inhibits
TCR-induced reactivation in latently infected CD4+ T cells. This
inhibition was observed at the transcriptional level and restricted
to PD-1+ cells (Supplementary Fig. 4a, b). Similarly, PD-1
engagement inhibited TCR-induced activation of the positive
transcription elongation factor b (P-TEFb), a master regulator of
HIV transcription (82% inhibition of CDK9 phosphorylation,
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p= 0.01, Fig. 2b and 61% inhibition of cyclin T1 expression, p=
0.02, Fig. 2c)25.
PD-1 blockade enhances viral production ex vivo. Since our
results indicated that PD-1 engagement prevents HIV reacti-
vation from latency, we sought to determine if PD-1 blockade
could facilitate latency reversal. We stimulated large numbers of
CD8- and CD56-depleted peripheral blood mononuclear cells
(PBMCs) from HIV-infected individuals on suppressive ART
with the latency reversing agent bryostatin in the presence of a
PD-1 blocking antibody (pembrolizumab) or the corresponding
isotype control. HIV production was greatly increased by PD-1
blockade (median fold-increase over isotype control
(interquartile range (IQR)) 36.00 (7.90–47.25), Fig. 2d) without
enhancing T-cell activation nor affecting cell viability (Fig. 2e).
Of note, blocking PD-1 also enhanced viral production when
latently infected CD4+ T cells were stimulated with suboptimal
concentrations of the superantigens Staphylococcal Enterotox-
ins A and B (SEA and SEB) (median fold-increase over isotype
control (IQR) 4.23 (2.04–71.96), Supplementary Fig. 5a).
Interestingly, PD-1 blockade significantly increased the levels of
cytokine production (Supplementary Fig. 5b, c) but had mini-
mal effects on markers of T-cell homeostasis, proliferation,
survival and activation upon TCR or IL-7 stimulations (Sup-
plementary Fig. 6a–g). Together, these experiments indicated
that blocking PD-1 increases viral production from latently
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Fig. 1 PD-1 engagement inhibits viral production in CD4+ T cells from untreated HIV-infected individuals. a Relative viral production measured by p24
release in 3-days culture supernatants of CD4+ T cells isolated from HIV-infected untreated individuals and stimulated through the TCR in the presence or
absence of PD-L1 (means and standard deviations from n= 5 donors). p Values were obtained from paired t test analysis. b Same as in a with p24
measurements at day 3, 6, and 9 in CD4+ T cells supernatants from a representative donor. c Relative viral production measured by p24 as in b (means
and standard deviations from n= 5 donors). p Values reflect differences between the PD-L1 and isotype control conditions and were obtained from paired t
test analysis. d Viral production normalized to the CD3/CD28 condition measured by RT-PCR in supernatants of sorted PD-1+ and PD-1− TTM cells
subjected to stimulation as in a (means and standard deviations from n= 4 donors). p Values were obtained from paired t test analysis. e Luciferase
activity (normalized to the CD3/CD28-isotype ctrl condition) in CD4+ T cells transfected with an LTR-luciferase reporter construct and stimulated as in
a (means and standard deviations from n= 7 independent experiments). p Values were obtained from paired t test analysis. Source data are provided as a
Source Data file
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infected cells in response to the latency reversing agent bryos-
tatin and to suboptimal TCR stimulation without enhancing T-
cell activation.
Our in vitro findings were further supported by the progressive
decrease in total and integrated HIV DNA as well as in cell-
associated HIV RNA (4-, 3-, and 19-fold decreases, respectively)
observed in a virally suppressed individual who received
pembrolizumab for metastatic melanoma (Supplementary Fig. 7).
We acknowledge that this case report does not prove latency
reversal in vivo since a reduction in HIV persistence markers
could result from multiple mechanisms, including immune-
mediated effects. Nonetheless, this observation supports the
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Fig. 2 PD-1 engagement inhibits viral reactivation from latently infected cells and its blockade enhances viral production ex vivo. a Relative viral production
measured by RT-PCR in 3-days culture supernatants of CD4+ T cells isolated from virally suppressed individuals and stimulated through the TCR in the
presence or absence of PD-L1 (means and standard deviations from n= 8 donors). p Values were obtained from paired t test analysis. b Level of CDK9
phosphorylation (Ser175) expression in CD4+ T cells isolated from virally suppressed individuals after 12 h of stimulation through the TCR in the presence
or absence of PD-L1 (black bars represent average MFI from n= 4 donors). p Values were obtained from paired t test analysis. c Level of cyclinT1
expression as in b (black bars represent average MFI from n= 4 donors). p Values were obtained from paired t test analysis. d Viral production measured
by RT-PCR in 6-days culture supernatants of CD8- and CD56-depleted PBMCs isolated from virally suppressed individuals and stimulated with bryostatin
(18 h pulse at 10 nM) in the presence of PD-1 blocking monoclonal antibody or the appropriate isotype control (10 μg/mL) (median and interquartile range
from n= 5 donors). p Values were obtained from paired t-test analysis of the log transformed value +1. e CD4+ T cells activation measured by CD69,
Ki67, CD25, and HLA-DR/CD38 expressions and cell viability measured by flow cytometry after 6 days of culture as described in Fig. 2d. Source data are
provided as a Source Data file
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concept that PD-1 blockade can reduce the latent reservoir
in vivo.
Discussion
Latently infected cells represent the major obstacle to a cure for
HIV infection26. Memory CD4+ T cells are constantly exposed to
homeostatic signals required for their maintenance (IL-7, IL-15,
and perhaps interactions with self-peptide MHCII complex).
However, the long half-life of memory CD4+ T cells and the
modest activity of the majority of latency reversing agents27
suggest that inhibitory mechanisms may continuously abrogate
viral reactivation in latently infected cells. Our results indicate
that HIV preferentially persists in PD-1+ cells and that the
engagement of PD-1 potently inhibits viral reactivation. It was
recently reported that PD-1 suppresses T-cell function primarily
by inactivating CD28 signaling28,29, which provides a potential
explanation for the preferential persistence of HIV in PD-1+ TCM
and TTM cells, two subsets that express high levels of CD28.
The ability of TCR signaling to enhance HIV transcription has
been associated to release of P-TEFb from an inactive complex
through an ERK-dependent pathway30. In this study, we provide
mechanistic evidence that PD-1 engagement inhibits the P-TEFb
signaling pathway, which likely contributes to the inhibition of
HIV production. In addition to its immediate effect on HIV
production, PD-1 engagement may also lead to a prolonged
silencing of the HIV promoter through metabolic and epigenetic
reprogramming of T cell31–33.
Importantly, our observations demonstrate that HIV reacti-
vation is enhanced by PD-1 blockade in CD4+ T cells from virally
suppressed individuals ex vivo. Of note, we observed that PD-1
blockade potentiates latency reversal without inducing global T-
cell activation, in spite of increased levels of TCR-induced cyto-
kine production. These observations suggest that cytokine
secretion and HIV reactivation can be uncoupled from the
induction of T-cell activation. This is in line with studies
reporting that reduced levels of IL-2 production is sensitive
hallmark of PD-1 engagement. Since NF-κB is an important
factor positively regulating both IL-2 and HIV transcription, it is
possible that activation of this transcription factor is involved in
the increased levels of viral production following PD-1 blockade.
As such, increased IL-2 secretion following PD-1 blockade was
also reported in vivo34. Since the level of PD-1 expression on
distinct CD4+ T-cell subsets impacts the effect of PD-1/PD-L1
blockade11, it remains to be determined if HIV latency can be
reverted in all cellular HIV reservoirs using this strategy. Of note,
since additional co-inhibitory receptors have been associated with
HIV persistence in different subsets16,17,35 combination of
immune-checkpoint blockers may be necessary to achieve opti-
mal latency reversal.
We observed a progressive decline of several markers of HIV
persistence throughout treatment with pembrolizumab in an
individual receiving this antibody for malignant melanoma. This
case illustrates the ability of PD-1 blockade to reduce the size of
the HIV reservoir in some individuals, which is consistent with
other studies demonstrating an effect of PD-1 or CTLA-4
blockade on HIV reservoir dynamics22,36,37. Since this effect is
not observed in all virally suppressed individuals38, results from
larger ongoing studies enrolling HIV-infected participants
receiving immunotherapy for the treatment of malignancies are
warranted.
The potential toxicity of these immunotherapies and the risk
benefit ratio for HIV-infected individuals on stable suppressive
ART should be considered carefully. To our knowledge, safety
data in HIV-infected noncancer patients are not yet available.
However, several reports in individuals with HIV and cancer38–40
indicate that the frequency of immune related adverse events due
to PD-1 blockade in the setting of HIV appears to be similar to
non-HIV. Of note, in all these studies including ours, the impact
of PD-1 blockade on the HIV reservoir was assessed in peripheral
blood. Knowing that CD4+ T cells expressing PD-1 are found at
high frequencies in preferential anatomical HIV reservoirs such
as gut, lymph nodes and adipose tissue during ART19,41,42,
assessing latency reversal and HIV reservoir dynamics after PD-1
blockade administration would require analyzing tissues in which
this process is more likely to occur and collecting samples shortly
after administration of the PD-1 blocking antibody.
To conclude, our findings suggest that PD-1 may provide
latently infected cells with a selective advantage to persist during
ART by continuously inhibiting viral reactivation and provide the
rationale for evaluating immune checkpoint blockers in curative
strategies.
Methods
Study population. HIV-seropositive individuals on stable suppressive ART,
chronically infected individuals with no history of ART and uninfected controls
enrolled in this study. All participants signed inform consent approved by the
Martin Memorial Health Systems (FL, USA), the UCSF (CA, USA), the Royal
Victoria Hospital and the CHUM hospital (QC, Canada) review boards (IRB #10-
1320, Ref # 068192 and FWA #00004139, respectively). The participant with
metastatic malignant melanoma who received pembrolizumab-based immu-
notherapy was virally suppressed for more than 3 years and signed inform consent.
Blood was collected 8 days after the second administration of the antibody and 20
to 40 days after all subsequent treatment cycles over a period of 4 months. We
complied with all relevant ethical regulations for work with human participants.
Immunophenotyping. PBMCs were isolated from peripheral blood and leuka-
pheresis using Ficoll–Paque density gradient centrifugation. Single-cell suspensions
from lymph node, rectum, colon, and ileal biopsies were prepared as previously
described41,43. Cryopreserved PBMCs were thawed, washed and stained for phe-
notyping or cell sorting. To measure the expression of PD-1 in subsets of memory
CD4+ T cells, the following antibody panel was used: CD3-Alexa700 (clone
UCHT1, BD#557943), CD4-QDot605 (clone S3.5, Invitrogen#Q10008), CD8-PB
(clone RPA-T8, BD#558207), CD14-V500 (clone M5E2, BD#561391), CD19-
AmCyan (clone SJ25C1, BD#339190), LIVE/DEAD Aqua marker (Invi-
trogen#L34957), CD45RA-APC-H7 (clone HI100, BD#560674), CD27-BV650
(clone O323, Biolegend#302828), and CCR7-PE-Cy7 (clone 3D12, BD#557648)
and PD-1-APC (clone MIH4, eBioscience#17-9969-42). Gates were defined using
fluorescence minus one controls. CD4+ T-cell subsets were identified by CD27,
CD45RA, and CCR7 expression on CD4+ T cells after exclusion of dump positive
cells (LIVE/DEAD, CD14 and CD19). PD-1 was measured in gated CD4+ T-cell
subsets including naïve CD4+ T cells (CD3+ CD8-CD4+ CD45RA+ CCR7+
CD27+), central memory CD4+ T cells (CD3+ CD8− CD4+ CD45RA− CCR7+
CD27+), transitional memory CD4+ T cells (CD3+ CD8− CD4+ CD45RA−
CCR7− CD27+), effector memory CD4+ T cells (CD3+ CD8-CD4+ CD45RA−
CCR7− CD27−) and terminally differentiated CD4+ T cells (CD3+ CD8-CD4+
CD45RA+ CCR7− CD27−). To measure the expression of PD-1 ligands (PD-L1
and PD-L2) the following antibody panel was used: CD3-PB (clone UCHT1,
BD#558117), CD4-Alexa700 (cloneRPA-T4, BD#557922), CD8-PerCPCy5.5 (clone
RPA-T8, BD#560662), CD14-FITC (clone M5E2, BD#555397), LIVE/DEAD Aqua
marker (Invitrogen#L34957), CD45RA-APC-H7 (clone HI100, BD#560674), PD-
1-APC (clone MIH4, eBioscience#17-9969-42), PD-L1-PE-Cy7 (clone MIH1,
BD#558017), and PD-L2-PE (clone MIH18, BD#558066). Data were acquired on a
BD LSR II flow cytometer using the FACSDiva software (Becton Dickinson) and
analyzed using Flow Jo version 9 (Treestar).
Cell sorting. Central, transitional and effector memory CD4+ T cells were sorted
based on their expression of PD-1. The antibodies used for sorting were similar
than those used for phenotyping (Supplementary Fig. 8). In a second set of
experiments, total memory CD4+ T cells (CD3+ CD4+ CD45RA−) were sorted
based on their expression of PD-1. Sorted cells were collected using a FACSAria II
cell sorter (Becton Dickinson).
Isolation of total CD4+ T cells. Total CD4+ T cells were isolated from cryo-
preserved PBMCs using magnetic negative selection as per the manufacturer’s
protocol (Stem Cell Technologies, Vancouver, Canada).
Quantification of integrated HIV DNA. Total CD4+ T cells or sorted CD4+ T-
cell subsets were used to measure the frequency of cells harboring integrated HIV
DNA by real time nested polymerase chain reaction (PCR)44. Briefly, cells were
lysed by proteinase K digestion. Cell lysates were directly used for HIV DNA
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quantifications. Integrated HIV-1 DNA was amplified with two Alu primers
together with a primer annealing the LTR/gag region (Supplementary Table 1). In
all PCR reactions, primers specific for the CD3 gene were added to precisely
quantify the cell input. In a second round of PCR, appropriate primers and probes
were used to amplify HIV sequences from the first round of amplification. Inner
primers specific for the CD3 gene were used in a separate reaction to determine cell
input. The number of copies of integrated HIV-1 DNA was calculated by using
serial dilutions lysed ACH-2 cells as a standard curve. Results were expressed as
numbers of HIV copies per million cells.
Quantification of Tat/rev inducible multiply spliced HIV RNA. The frequency
of CD4+ T cells with inducible multiply spliced HIV RNA was determined using
the TILDA6. Briefly, cells were stimulated with phorbol myristate acetate (PMA;
100 ng/mL) and ionomycin (1 µg/mL) for 12 h. Serial dilutions of the stimulated
cells (18,000; 9000; 3000, and 1000 cells; 24 replicates per dilution) were distributed
in a 96 well plate containing real time PCR (RT-PCR) buffer. Multiply spliced HIV
RNA was quantified by semi nested real time PCR using primers specific for the
tat/rev region (Supplementary Table 1). The frequency of positive cells was cal-
culated using the maximum likelihood method and this number was then
expressed as a frequency of cells with inducible msHIV RNA per million cells.
Quantification of cell-associated and cell-free HIV RNA. Cell-associated RNA
were extracted using the RNeasy kit (Qiagen). Alternatively, freshly collected cell
culture supernatants were ultracentrifuged for 1 h at 25,000g to pellet HIV parti-
cles. By using this procedure, only packed viral RNAs were quantified, excluding
HIV RNAs that are passively released in the medium as a consequence of cell
death. Viral RNAs were extracted using the Qiamp viral RNA kit (Qiagen) and
quantified using an ultrasensitive semi-nested real time RT-PCR with a detection
limit of a single copy of HIV RNA per reaction45.
Quantification of viral production by p24 ELISA. Viral production was measured
by quantification of the p24 antigen by a sensitive in-house p24 ELISA46. In this
enzymatic assay, 183-H12-5C (coating) and 31-90-25 (conjugated to biotin) anti-
bodies were used in combination to quantify p24 levels.
Quantification of replication-competent virus. Sorted memory PD1+ and PD1−
CD4+ T cells were activated for 3 days with coated anti-CD3 (clone OKT3) and
soluble anti-CD28 (clone CD28.2) in presence of anti-PD-1 antibody (pem-
brolizumab 10 µg/mL) in limiting dilution (from 1.5 million cells to 0.05 million
cells). After 3 days of stimulation, cells were washed 2 times with RPMI and co-
cultured for an additional 12 days with PHA/IL-2 activated CD4+ T cells from two
HIV negative donors at a ratio 1:3 in medium containing IL-2 (5 ng/mL) and anti-
PD-1 antibody (pembrolizumab 10 µg/mL, Merck). Culture were split twice weekly;
half of cell culture supernatants were collected for quantification of the viral
production by p24 ELISA. Infectious Unit per Million cells was determined based
on the number of wells positive for p24 using the maximum likelihood method
(http://silicianolab.johnhopkins.edu/).
PD-1 engagement. CD4+ T cells were cultured in RPMI 1640 complemented with
10% fetal bovine serum and 1% penicillin–streptomycin in the presence or absence
of ARVs [100 nM efavirenz (EFV), 180 nM zidovudine (AZT), and 200 nM ralte-
gravir (RAL)]. Cells were stimulated with CELLection Pan Mouse IgG (Invitrogen)
coated with anti-CD3 (UCHT1), anti-CD28 (CD28.2), and PD-L1 chimeric protein
(kindly provided by G.J. Freeman) or the appropriate isotype control (IgG2a).
Beads were added to CD4+ T cells in a 1:2 (cell:bead) ratio and kept in culture for
the entire duration of the experiment (up to 9 days).
PD-1 blockade. Fifteen to 25 × 106 CD8-depleted PBMCs or CD56- and CD8-
depleted PBMCs from virally suppressed individuals were stimulated with SEA/
SEB (0.3 ng/mL), IL-7 (10 ng/mL), or bryostatin (10 nM, 18 h exposure) in the
presence or absence of anti-PD-1 (pembrolizumab 10 µg/mL) or the appropriate
isotype control, in the presence of ARVs. Viral production was measured in cell
culture supernatants after 3 or 6 days of culture as described above. Samples with
spontaneous viral production (>10 HIV RNA copies in the nonstimulated condi-
tion) and/or inconsistent replicate values attributed to low frequency of reservoir
cells were excluded. Cytokine production was measured by electro-
chemiluminescence using multi-array technology (Meso Scale Discovery). Bcl-2,
CD69, Ki67, CD25, and HLA-DR/CD38 expressions, phosphorylation of STAT5
and Akt and cell viability were measured by flow cytometry using the following
antibodies: Bcl-2-V450 (clone Bcl-2/100, BD#560637), CD69-APC (clone FN50,
BD#555533), CD25-BUV737 (clone 2A3, BD#564385), HLA-DR-BUV395 (clone
G46-6, BD#564040), CD38-PE (clone HIT2, BD#555460), pSTAT5-AF647 (pY694,
BD#612599), and pAkt-PE-CF594 (pS473, BD#562465). PD-1 receptor occupancy
by the blocking antibody was measured in all experiments by flow cytometry and
was constantly higher than 90%.
P-TEFb activity. Phosphorylation of CDK9 (Ser175) (provided by Merck) and
level of expression of CyclinT1 were measured by flow cytometry after 12 h
stimulation of CD4+ T cells isolated from virally suppressed individuals upon PD-
1 engagement25. Briefly, titrated antibodies (CD3-FITC, CD4-AF700, CD8-PB,
CD45RA-APC-H7, PD-1-BUV737) were added to 2 million cells in 50 μl of PBS in
the presence of Live/Dead Dye for 30 min at 4 °C. Cells were fixed with For-
maldehyde 4% (methanol free) for 20 min at room temperature and then per-
meabilized with Perm/Wash Buffer (BD#554723) for 30 min at 4 °C. Intracellular
stainings for pCDK9 (pCDK9-AF647) and CyclinT1 (CyclinT1-TRITC, Santa-
Cruz#8127) were conducted in Perm/Wash Buffer for 20 min at room temperature.
LTR-luciferase. Memory CD4+ T cells were isolated by negative magnetic selec-
tion (StemCell) from fresh PBMCs obtained from HIV-negative individuals. After
24 h of TCR stimulation (0.1 µg/mL coated anti-CD3 and 1 µg/mL soluble anti-
CD28), cells were nucleofected with pBlue3′LTR-lucB (NIH AIDS Reagent Pro-
gram) using Amaxa technology (Lonza). Twenty-four hour postnucleofection, cells
were stimulated with CD3/CD28 ± PD-L1 beads, as described above. Luciferase
activity was measured after 6 h of stimulation.
Statistical analysis. We performed Pearson’s correlation, t test and
Mann–Whitney U tests with Prism 6.0 software. We considered two-sided p values
of less than 0.05 significant.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request. Source data underlying all figures are provided as a
Source Data file.
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